Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Fenretinide (4-HPR) 是一种可口服的合成类维生素 A 衍生物,具有潜在的抗肿瘤和化学预防活性。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
5 mg | ¥ 229 | 现货 | ||
10 mg | ¥ 373 | 现货 | ||
50 mg | ¥ 648 | 现货 | ||
100 mg | ¥ 995 | 现货 | ||
200 mg | ¥ 1,498 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 385 | 现货 |
产品描述 | Fenretinide (4-HPR) is an orally-active synthetic retinoid derivative with potential antineoplastic and chemopreventive activities. |
体外活性 | Fenretinide exerts not just acute but also long term antitumor activity in selected T-ALL cell lines. Fenretinide inhibits DES activity in CCRF-CEM leukemia cells in a dose and time-dependent manner which leading to a concomitant increase of the endogenous cellular dhCer content. Fenretinide (3 μM)-induced dhCer accumulation in both CCRF-CEM and Jurkat cells[1]. Ceramide inhibition with fenretinide protects insulin signaling. Fenretinide prevents lipid-induced reductions in insulin-stimulated glucose uptake[2]. Fenretinide inhibits OVCAR-5 cell proliferation and viability at concentrations higher than 1 microM, with 70-90% growth inhibition at 10 microM. Fenretinide (1 microM) significantly inhibits OVCAR-5 invasion after 3 days preincubation. Endothelial cells treated with 1 microM 4-HPR fails to form tubes, but forms small cellular aggregates[4]. |
体内活性 | Fenretinide (10 mg/kg, i.p.) selectively inhibits ceramide accumulation HFD-fed male C57Bl/6 mice. Fenretinide treatment improves glucose tolerance and insulin sensitivity as determined by both glucose and insulin tolerance tests[2]. The addition of 25 mg/kg ketoconazole to Fenretinide increased 4-HPR plasma levels in NOD/SCID mice[3]. |
细胞实验 | Fenretinide is dissolved in DMSO. Standard XTT assay is used to determine cell viability. For fenretinide-only treatments, cells are plated in 96-well plates at 750,000 cells/mL and 100 μL/well. After 4 h, treatments are added on 50 μL/well obtaining a final density of 500,000 cells/mL and final volume of 150 μL/well. Four replicates are used per experimental condition. XTT reagent mixture is added 4 h before the end of selected treatment period and absorbance at 490 nm is determined per each well. A slightly modified protocol is used for analysis of the effect of myriocin (final concentration of 100 nM) or antioxidant on Fenretinide treatment. Briefly, cells are seeded on 60 mm culture dishes and myriocin or antioxidants added after 4 h. Fenretinide treatment is added 2 h later and cells are plated in quadruplicates in 96 well plates (150 μL/well). |
别名 | 4-HPR, MK-4016, 芬维A胺, 4-hydroxy(phenyl)retinamide |
分子量 | 391.55 |
分子式 | C26H33NO2 |
CAS No. | 65646-68-6 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 39.2 mg/mL(100 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.554 mL | 12.7698 mL | 25.5395 mL | 63.8488 mL |
5 mM | 0.5108 mL | 2.554 mL | 5.1079 mL | 12.7698 mL | |
10 mM | 0.2554 mL | 1.277 mL | 2.554 mL | 6.3849 mL | |
20 mM | 0.1277 mL | 0.6385 mL | 1.277 mL | 3.1924 mL | |
50 mM | 0.0511 mL | 0.2554 mL | 0.5108 mL | 1.277 mL | |
100 mM | 0.0255 mL | 0.1277 mL | 0.2554 mL | 0.6385 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Fenretinide 65646-68-6 Autophagy Metabolism Retinoid Receptor 4-HPR Retinoic acid receptors MK4016 MK-4016 Inhibitor 芬维A胺 RAR/RXR 4-hydroxy(phenyl)retinamide inhibit MK 4016 Retinoid X receptors inhibitor